Carra A. P635 ECTRIMS 2004. Odds ratio for relapse, disability progression favors glatiramer over interferon groups.
Based on pooled data of four open nonrandomized trials. Patients n= 695 with 135 patients on GA having less relapses and accumulated disability.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment